Advertisement
SNPHF vs SNPHY
To understand the difference between Santen Pharmaceutical Co. Ltd. (SNPHF) vs. Santen Pharmaceutical Co. Ltd. - ADR (SNPHY) it is enough to know the definitions of ADR
ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SNPHF’s FA Score shows that 0 FA rating(s) are green whileSNPHY’s FA Score has 0 green FA rating(s).
- SNPHF’s FA Score: 0 green, 5 red.
- SNPHY’s FA Score: 0 green, 5 red.
Price Growth
SNPHF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while SNPHY (@Pharmaceuticals: Major) price change was +2.23% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.52%. For the same industry, the average monthly price growth was +4.77%, and the average quarterly price growth was +8.25%.
Reported Earning Dates
SNPHY is expected to report earnings on May 13, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+0.52% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| SNPHF | SNPHY | SNPHF / SNPHY | |
| Capitalization | 3.26B | 3.26B | 100% |
| EBITDA | 17.2B | 17.2B | 100% |
| Gain YTD | 8.716 | 12.549 | 69% |
| P/E Ratio | 15.31 | 15.60 | 98% |
| Revenue | 270B | 270B | 100% |
| Total Cash | 62.3B | 62.3B | 100% |
| Total Debt | 40.1B | 40.1B | 100% |
SNPHF | SNPHY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 47 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 46 | 45 | |
P/E GROWTH RATING 1..100 | 81 | 85 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNPHF's Valuation (50) in the null industry is in the same range as SNPHY (50). This means that SNPHF’s stock grew similarly to SNPHY’s over the last 12 months.
SNPHF's Profit vs Risk Rating (100) in the null industry is in the same range as SNPHY (100). This means that SNPHF’s stock grew similarly to SNPHY’s over the last 12 months.
SNPHF's SMR Rating (100) in the null industry is in the same range as SNPHY (100). This means that SNPHF’s stock grew similarly to SNPHY’s over the last 12 months.
SNPHY's Price Growth Rating (45) in the null industry is in the same range as SNPHF (46). This means that SNPHY’s stock grew similarly to SNPHF’s over the last 12 months.
SNPHF's P/E Growth Rating (81) in the null industry is in the same range as SNPHY (85). This means that SNPHF’s stock grew similarly to SNPHY’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
Advertisement
SNPHF and
Correlation & Price change
A.I.dvisor tells us that SNPHF and RHHVF have been poorly correlated (+7% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SNPHF and RHHVF's prices will move in lockstep.
| Ticker / NAME | Correlation To SNPHF | 1D Price Change % | ||
|---|---|---|---|---|
| SNPHF | 100% | N/A | ||
| RHHVF - SNPHF | 7% Poorly correlated | +3.69% | ||
| PTKFY - SNPHF | 6% Poorly correlated | N/A | ||
| PTKFF - SNPHF | 2% Poorly correlated | N/A | ||
| RHHBY - SNPHF | 2% Poorly correlated | +1.87% | ||
| SNPHY - SNPHF | 1% Poorly correlated | -2.77% | ||
More | ||||
SNPHY and
Correlation & Price change
A.I.dvisor tells us that SNPHY and RHHBF have been poorly correlated (+9% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SNPHY and RHHBF's prices will move in lockstep.
| Ticker / NAME | Correlation To SNPHY | 1D Price Change % | ||
|---|---|---|---|---|
| SNPHY | 100% | -2.77% | ||
| RHHBF - SNPHY | 9% Poorly correlated | +1.99% | ||
| RHHVF - SNPHY | 9% Poorly correlated | +3.69% | ||
| RHHBY - SNPHY | 6% Poorly correlated | +1.87% | ||
| OTSKY - SNPHY | 3% Poorly correlated | +2.13% | ||
| SNPHF - SNPHY | 1% Poorly correlated | N/A | ||
More | ||||